562 related articles for article (PubMed ID: 29663291)
21. Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours.
Liu G; Wang C; He Y; E M
BMC Pharmacol Toxicol; 2019 Oct; 20(1):61. PubMed ID: 31661009
[TBL] [Abstract][Full Text] [Related]
22. High DCR and Better Survival in Patients with Advanced or Metastatic Gastric Cancer Receiving Anti-Angiogenic TKI plus Chemotherapy: A Real-World Study.
Nie C; Lv H; Chen B; Xu W; Wang J; Wang S; Liu Y; He Y; Zhao J; Chen X
Technol Cancer Res Treat; 2023; 22():15330338221150561. PubMed ID: 36632666
[No Abstract] [Full Text] [Related]
23. Efficacy and prognosis analyses of apatinib combined with S-1 in third-line chemotherapy for advanced gastric cancer.
Wu Q; Fu Y; Wen W; Xi T; Zhao G
J BUON; 2020; 25(2):987-994. PubMed ID: 32521896
[TBL] [Abstract][Full Text] [Related]
24. [Efficacy and Survival Analysis of Apatinib in Patients with Advanced Nonsquamous Non-small Cell Lung Cancer after Failure of First-line Treatment].
Wang X; Zhang W; Du W; Zhang X; Ren X; Cao S
Zhongguo Fei Ai Za Zhi; 2017 Nov; 20(11):761-768. PubMed ID: 29167006
[TBL] [Abstract][Full Text] [Related]
25. Apatinib, a novel VEGFR-2 tyrosine kinase inhibitor, for relapsed and refractory nasopharyngeal carcinoma: data from an open-label, single-arm, exploratory study.
Li L; Kong F; Zhang L; Li X; Fu X; Wang X; Wu J; Zhang F; Ren L; Zhang M
Invest New Drugs; 2020 Dec; 38(6):1847-1853. PubMed ID: 32363427
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic potentials of Apatinib in cancer treatment: Possible mechanisms and clinical relevance.
Fathi Maroufi N; Rashidi MR; Vahedian V; Akbarzadeh M; Fattahi A; Nouri M
Life Sci; 2020 Jan; 241():117106. PubMed ID: 31786193
[TBL] [Abstract][Full Text] [Related]
27. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
28. Apatinib for molecular targeted therapy in tumor.
Zhang H
Drug Des Devel Ther; 2015; 9():6075-81. PubMed ID: 26622168
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of efficacy and safety of apatinib treatment in advanced gastric cancer.
Yang Y; Wu X; Li F; Wang N; Zhang M; Sun T; Chen Z
J Cancer Res Ther; 2019; 15(2):365-369. PubMed ID: 30964112
[TBL] [Abstract][Full Text] [Related]
30. Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Kang YK; Ryu MH; Di Bartolomeo M; Chau I; Yoon H; Kim JG; Lee KW; Oh SC; Takashima A; Kryzhanivska A; Chao Y; Evesque L; Schenker M; McGinn A; Zhao Y; Lee J; Wyrwicz L; Boku N
Gastric Cancer; 2024 Mar; 27(2):375-386. PubMed ID: 38281295
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness analysis of apatinib treatment for chemotherapy-refractory advanced gastric cancer.
Chen HD; Zhou J; Wen F; Zhang PF; Zhou KX; Zheng HR; Yang Y; Li Q
J Cancer Res Clin Oncol; 2017 Feb; 143(2):361-368. PubMed ID: 27798730
[TBL] [Abstract][Full Text] [Related]
32. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.
Lin Y; Wu Z; Zhang J; Hu X; Wang Z; Wang B; Cao J; Wang L
Tumour Biol; 2017 Jun; 39(6):1010428317711033. PubMed ID: 28639910
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of the VEGFR2 inhibitor Apatinib for metastatic soft tissue sarcoma: Chinese cohort data from NCT03121846.
Liu X; Xu J; Li F; Liao Z; Ren Z; Zhu L; Shi Y; Zhao G; Bai X; Zhao J; Xing R; Teng S; Yang Y; Yang J
Biomed Pharmacother; 2020 Feb; 122():109587. PubMed ID: 31786466
[TBL] [Abstract][Full Text] [Related]
34. Population Pharmacokinetic and Covariate Analysis of Apatinib, an Oral Tyrosine Kinase Inhibitor, in Healthy Volunteers and Patients with Solid Tumors.
Yu M; Gao Z; Dai X; Gong H; Zhang L; Chen X; Zhong DF; Sy SK
Clin Pharmacokinet; 2017 Jan; 56(1):65-76. PubMed ID: 27379402
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of apatinib on multiple advanced-stage nongastric cancers.
Wu X; Wang H; Wu Y; Jin J; Zhan Y; Zhu G; Zhang F; Zhang C; Gan J; Li W
J Cancer Res Ther; 2019; 15(4):836-841. PubMed ID: 31436240
[TBL] [Abstract][Full Text] [Related]
36. Low-dose apatinib monotherapy in advanced chemotherapy-refractory small cell lung cancer: a case series and literature review.
Liu YY; Chen T; Shen D; Zhang WY; Wang CG; Jiang JH; Zeng DX
J Int Med Res; 2020 Mar; 48(3):300060519887276. PubMed ID: 31847652
[TBL] [Abstract][Full Text] [Related]
37. Clinical response to apatinib monotherapy in advanced non-small cell lung cancer.
Xu J; Liu X; Yang S; Zhang X; Shi Y
Asia Pac J Clin Oncol; 2018 Jun; 14(3):264-269. PubMed ID: 29243413
[TBL] [Abstract][Full Text] [Related]
38. Apatinib for Advanced Osteosarcoma after Failure of Standard Multimodal Therapy: An Open Label Phase II Clinical Trial.
Xie L; Xu J; Sun X; Tang X; Yan T; Yang R; Guo W
Oncologist; 2019 Jul; 24(7):e542-e550. PubMed ID: 30559126
[TBL] [Abstract][Full Text] [Related]
39. Treatment effect of apatinib combined chemotherapy as second-line or above therapy in patients with advanced gastric cancer or adenocarcinoma of the gastroesophageal junction.
Zhang F; Yin Y; Ni T; Zhang M; Zhou Z; Sun X; Kuang W; Li P
Pharmazie; 2020 Aug; 75(8):389-394. PubMed ID: 32758339
[TBL] [Abstract][Full Text] [Related]
40. Apatinib as targeted therapy for advanced bone and soft tissue sarcoma: a dilemma of reversing multidrug resistance while suffering drug resistance itself.
Yang QK; Chen T; Wang SQ; Zhang XJ; Yao ZX
Angiogenesis; 2020 Aug; 23(3):279-298. PubMed ID: 32333216
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
